-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on NewAmsterdam Pharma Co, Raises Price Target to $37

Benzinga·12/02/2025 18:14:58
Listen to the news
Goldman Sachs analyst Asad Haider maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Neutral and raises the price target from $30 to $37.